Global Obeticholic Acid Drug Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Obeticholic Acid Drug Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Obeticholic acid is a semi-synthetic bile acid analogue which has the chemical structure 6α-ethyl-chenodeoxycholic acid.
Obeticholic Acid Drug report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Obeticholic Acid Drug market is projected to reach US$ 240.4 million in 2029, increasing from US$ 309 million in 2022, with the CAGR of -2.4% during the period of 2024 to 2029. Demand from Primary Biliary Cirrhosis and Nonalcoholic Fatty Liver Disease are the major drivers for the industry.
The Ocaliva market is primarily driven by the urgent need for effective treatments for primary biliary cholangitis (PBC), a chronic liver disease that affects the bile ducts. Ocaliva, also known as obeticholic acid, is a medication used to manage PBC and improve liver function. The increasing prevalence of PBC, coupled with advancements in hepatology research and the focus on liver health, contributes to market growth. Moreover, the demonstrated benefits of Ocaliva in reducing serum alkaline phosphatase levels and delaying disease progression further propel adoption. However, challenges include managing potential side effects, optimizing dosing for individual patients, and addressing potential drug interactions. Navigating patient-specific treatment needs, ensuring long-term safety, and providing comprehensive monitoring are ongoing concerns. The market's success relies on continuous research in liver diseases, collaborations between pharmaceutical manufacturers and hepatologists, and comprehensive patient education on the benefits and potential risks of Ocaliva treatment while addressing the evolving challenges associated with liver disease management and treatment accessibility.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Obeticholic Acid Drug market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Intercept Pharmaceuticals
Dainippon Sumitomo Pharma
Segment by Type
5mg
10mg
Primary Biliary Cirrhosis
Nonalcoholic Fatty Liver Disease
Other
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Obeticholic Acid Drug market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Obeticholic Acid Drug, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Obeticholic Acid Drug industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Obeticholic Acid Drug in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Obeticholic Acid Drug introduction, etc. Obeticholic Acid Drug Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Obeticholic Acid Drug market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Obeticholic Acid Drug report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Obeticholic Acid Drug market is projected to reach US$ 240.4 million in 2029, increasing from US$ 309 million in 2022, with the CAGR of -2.4% during the period of 2024 to 2029. Demand from Primary Biliary Cirrhosis and Nonalcoholic Fatty Liver Disease are the major drivers for the industry.
The Ocaliva market is primarily driven by the urgent need for effective treatments for primary biliary cholangitis (PBC), a chronic liver disease that affects the bile ducts. Ocaliva, also known as obeticholic acid, is a medication used to manage PBC and improve liver function. The increasing prevalence of PBC, coupled with advancements in hepatology research and the focus on liver health, contributes to market growth. Moreover, the demonstrated benefits of Ocaliva in reducing serum alkaline phosphatase levels and delaying disease progression further propel adoption. However, challenges include managing potential side effects, optimizing dosing for individual patients, and addressing potential drug interactions. Navigating patient-specific treatment needs, ensuring long-term safety, and providing comprehensive monitoring are ongoing concerns. The market's success relies on continuous research in liver diseases, collaborations between pharmaceutical manufacturers and hepatologists, and comprehensive patient education on the benefits and potential risks of Ocaliva treatment while addressing the evolving challenges associated with liver disease management and treatment accessibility.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Obeticholic Acid Drug market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Intercept Pharmaceuticals
Dainippon Sumitomo Pharma
Segment by Type
5mg
10mg
Segment by Application
Primary Biliary Cirrhosis
Nonalcoholic Fatty Liver Disease
Other
Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Obeticholic Acid Drug market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Obeticholic Acid Drug, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Obeticholic Acid Drug industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Obeticholic Acid Drug in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Obeticholic Acid Drug introduction, etc. Obeticholic Acid Drug Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Obeticholic Acid Drug market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices